New pill for untreated intestinal lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new oral medication (golisitinib) in people with untreated intestinal T-cell lymphoma to see if it can help control the disease. The study focuses on safety and effectiveness, and is for those who have not had prior treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of intestinal lymphoma that has not been treated yet.
- Your doctor expects you to survive at least 12 weeks and your major organs (heart, lungs, liver, kidneys) are working well enough for the treatment.
- You agree to use effective birth control during treatment and for 6 months after the last dose.
- You have not had any cancer treatment (like chemotherapy or radiation) or major surgery within the last 28 days.
- You do not have active infections like tuberculosis, HIV, hepatitis B or C, or other serious infections.
- You do not have serious heart problems, such as heart failure, recent heart attack, or irregular heartbeat requiring medication.
- You have not had an allogeneic stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral pill called golidocitinib (a JAK1 inhibitor) as the first treatment for people newly diagnosed with peripheral T-cell lymphoma. The pill targets a pathway that cancer cells use to grow, and the goal is to shrink tumors or slow the disease.
This trial tests a new pill (golidocitinib) combined with standard chemotherapy for people with a specific type of lymphoma that hasn't been treated before. The goal is to see if adding the pill helps control the cancer better than chemo alone.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a new targeted pill (golidocitinib) combined with two standard chemotherapy drugs (gemcitabine and oxaliplatin, known as GemOx) for people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination is safe and works better than current options.
Hear when a new Enteropathy Associated T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.